top of page

Democratizing Drug Delivery: Lipid Nanoparticles Changing the Game

Imagine having access to cutting-edge cationic lipids that can revolutionize drug delivery – at affordable prices.



At Carcell, we understand that researchers want to have a drug-delivery solution. However, with the limited bandwidth most scientists have, it is hard to allocate the time, resources, and expertise to simultaneously develop both a drug payload and a delivery vehicle.


Carcell have developed a number of cationic lipids: see our recently published patent applications PCT/CN2023/085921 and PCT/CN2023/085894. These lipids can be used to produce lipid nanoparticles (LNPs), to deliver your drug safely and effectively to subjects. The LNPs may be used to deliver:

  • a RNA payload, for example, the LNPs may be used to deliver an RNA payload, e.g. mRNA, tRNA, siRNA, ASO, miRNA, lncRNA, aptamer, circRNA, and self-replicating RNA;

  • a DNA payload, such as linear plasmids, nanoplasmids, covalently-closed DNA, and oligonucleotides

  • protein and peptide payloads; and

  • small and large molecule payloads.


By encapsulating these payloads, gene/protein expression can be modulated and/or specific molecules of interest can be delivered to a particular organ, tissue or cell of interest within a subject’s body.


We envisage that the nucleic acid loaded nanoparticles (e.g. mRNA loaded nanoparticles) may find utility in applications such as the treatment of cancers (e.g. carcinoma, sarcoma, lymphoma, leukemia, solid tumors, blood cancers and blastoma), immune-oncology, autoimmune diseases, gene editing, prophylactic/therapeutic vaccines for infectious diseases (e.g. viral infections) and cancer, anti-microbials, and for use in chronic diseases.


Preferred LNP compositions may be made from our polymers and include 0.05 – 0.5 mg/mL mRNA in a buffered aqueous solution between pH 6 and pH 8. We are also able to customize our lipids, such as through the use of PEG-free formulations and the addition of targeting moieties, which allows us to increase the potency and stability of the LNPs.


Our lipids are not only cost effective but have also been rigorously tested in vivo.


We are actively looking for customers to license our lipid technologies and are looking for ambitious partners as we democratize the access to potent lipids and empower the development of next-generation cell and gene therapies, vaccines and other drugs that require a non-viral delivery vehicle. We also offer end-to-end solutions in the journey to create new drug delivery vehicles.


Reach out to us today to explore potential collaborations to accelerate your research.


For more information, please visit https://carcell.com/lnp and contact contact@carcell.com.

Kommentare


bottom of page